Ignite Creation Date:
2025-12-18 @ 9:37 AM
Ignite Modification Date:
2025-12-23 @ 10:40 PM
Study NCT ID:
NCT07211178
Status:
None
Last Update Posted:
2025-10-07 00:00:00
First Post:
2025-09-19 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Sponsor:
None
Organization:
Study Overview
Official Title:
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Status:
None
Status Verified Date:
2025-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GEMINI Breast
Brief Summary:
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later.
A new, powerful way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA.
This research aims to see if finding this cancer DNA in the blood can help us predict if a patient's cancer will return. It also helps us find out if the treatment is working. This noninvasive test can help doctors catch the cancer early-before it can be seen on an imaging scan-allowing them to start new treatments sooner.
Ultimately, the results of this research will help doctors better manage breast cancer and develop new and improved tests and treatments.
A new, powerful way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA.
This research aims to see if finding this cancer DNA in the blood can help us predict if a patient's cancer will return. It also helps us find out if the treatment is working. This noninvasive test can help doctors catch the cancer early-before it can be seen on an imaging scan-allowing them to start new treatments sooner.
Ultimately, the results of this research will help doctors better manage breast cancer and develop new and improved tests and treatments.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: